Stone Ridge Asset Management’s Corcept Therapeutics CORT Stock Holding History

Stone Ridge Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-23,604	Closed	-$334K	–	971
2019 Q3	$334K	Sell	23,604 -1,500	-6%	-$18.4K	0.02%	824
2019 Q2	$280K	Buy	25,104 +4,300	+21%	+$47.9K	0.02%	936
2019 Q1	$244K	Hold	20,804	–	–	0.01%	979
2018 Q4	$278K	Sell	20,804 -6,200	-23%	-$81.9K	0.02%	1009
2018 Q3	$379K	Sell	27,004 -2,200	-8%	-$30.7K	0.02%	970
2018 Q2	$459K	Hold	29,204	–	–	0.03%	830
2018 Q1	$480K	Sell	29,204 -2,100	-7%	-$38.9K	0.03%	804
2017 Q4	$565K	Buy	+31,304	New	+$567K	0.04%	729

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stone Ridge Asset Management's CORT Position: Q4 2019 in Review

Stone Ridge Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2019, closing a stake of 23,604 shares — an estimated $334K sold.

Stone Ridge Asset Management first reported a position in CORT in Q4 2017 and held it in 8 quarters. The position peaked at $565K in Q4 2017. 205 funds tracked by Wall St. Rank hold CORT as of Q4 2019.

Stone Ridge Asset Management reported no remaining Corcept Therapeutics position as of Q4 2019 after selling out during the quarter.
Stone Ridge Asset Management sold 23,604 Corcept Therapeutics shares in Q4 2019, an estimated $334K.
Stone Ridge Asset Management first reported a position in Corcept Therapeutics in Q4 2017 and held it in 8 quarters.
Stone Ridge Asset Management's Corcept Therapeutics position peaked at $565K in Q4 2017.
205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2019.

Based on Stone Ridge Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.